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   Rheumatoid arthritis (RA) is an autoimmune chronic disease characterized by 
inflammation of peripheral joints with a various degree of systemic involvement. The 
pathogenesis is partly understood. Adaptive immunity plays indeed a pivotal role in 
inducing and maintaining the inflammatory process. Several cells belonging to the 
adaptive immune system have been associated to specific histological synovial 
patterns and clinical findings; among these, T helper (Th) lymphocytes have been 
exhaustively studied in RA due to their capability of producing cytokines and 
chemokines, migrating into articular sites and activating other immune or resident 
cells.  
   The pool of Th cells comprehends many subsets, each of which plays a precise role 
in inducing, tuning and repressing the immune response. Over the past twenty years, 
five distinct Th cell populations, properly named Th1, Th2, Th17, Th22 and Th9 cells, 
along with a counterpart of T cells with immune-repressive properties (T regulatory 
cells) have been described and characterized.   
   Th9 cells develop under stimulation with Tissue Growth Factor-beta (TGF-β) and 
Interleukin-4 (IL-4) either from naïve or primed Th lymphocytes. They prevalently 
synthetize IL-9, but, in vitro, the production of IL-10, IL-17, IL-21 and IL-22 has been 
also reported.   
   Th9 lymphocytes seem to be involved in the immunological responses underlying 
parasitic infections and allergic diseases. Neutralization of IL-9 worsens the 
symptomatic course of infestations while ameliorating the allergic manifestations. 
Some authors have demonstrated that Th9 cells take part to the pathogenesis of 
experimental autoimmune encephalomyelitis, systemic lupus erythematosus, systemic 
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sclerosis, psoriatic arthritis and RA. Th9 lymphocytes are increased in the bloodstream 
and in the synovial membranes of RA patients, being their percentage directly related 
to the degree of lymphoid organisation and to the production of autoantibodies, like 
anti-citrullinated peptide antibodies (ACPAs). However, it is unclear whether Th9 
lymphocytes could be involved in the response to the therapy, or in the 
immunogenicity of biologic agents.   
 
Aim 
   Primary objective: to evaluate the prevalence of Th9 lymphocytes in the peripheral 
blood of RA patients, assigned or not to an immunosuppressant treatment (including 
conventional drugs and infliximab), and to assess the immunogenicity of infliximab by 
detecting changes in Th9 percentages following an in vitro stimulation test.  
   Secondary objective: to compare the Th9-related immunogenicity of infliximab 
originator with that of its biosimilar compound (CT-P13, Remsima®), and to evaluate 




   We collected peripheral blood mononuclear cells (PBMCs) from 55 consecutive RA 
outpatients according to ACR/EULAR 2010 criteria and 10 healthy controls. We 
enrolled 15 subjects affected by RA not treated with immunosuppressive drugs, 20 
patients successfully treated with branded infliximab, and 20 patients who 
discontinued branded infliximab due to adverse events or inefficacy. Allowed drugs 
included prednisone (< 10 mg/day), methotrexate (< 15 mg/week), sulphasalazine (< 3 
g/day), hydroxychloroquine (< 400 mg/day) and, in the group of non responder 
patients, intravenous (i.v.) abatacept (10 mg/kg every 4 weeks), i.v. tocilizumab (8 
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mg/kg every 4 weeks), subcutaneous (s.c.) etanercept (50 mg once a week) and s.c. 
certolizumab pegol (200 mg every other week). The PBMCs were cultured 
with/without 50 µg/mL infliximab originator (Remicade®) or 50 µg/mL infliximab 
biosimilar (Remsima®), 50 µg/mL Human IgG1kappa and 50 µg/mL recombinant 
Human IgG Fc for 18 hours, and the percentage of Th9 cells was assessed by means of 
flow cytometry. Th9 lymphocytes were firstly identified as IFNγ-, IL-4-, IL-17-, IL-9-
secreting CD4+ T cells, and, in a second time, as PU.1+, IRF4+, IL-9+ CD4+ cells. 
Furthermore, the markers CCR7 and CD45RA were used to distinguish naïve from 
memory IL-9-producer cells. 
 
Results 
   In unstimulated condition, untreated RA patients showed the highest percentages of 
Th9 lymphocytes, either assessed according to cytokine or transcriptional profile, 
which was also higher in overall RA patients than in healthy controls.  
   The higher frequency of Th9 cells in RA patients was not associated with higher 
levels of anti-nuclear autoantibodies or other autoantibody subsets, or with a higher 
likelihood of experiencing an adverse event or lack of efficacy on infliximab 
treatment.  
   The percentage of PU.1+, IRF4+ Th9 cells, but not that of IL-9+, IFNγ-, IL-4-, IL-
17- CD4+ cells, increased following the exposure to branded infliximab in the group 
of non responder RA patients, although these data were not confirmed after biosimilar 
infliximab exposure.  
   Furthermore, when IL-9 producing T cells were subdivided according to the 
expression of the markers CD45RA and CCR7, CCR7+, CD45RA- central memory 
and CCR7-, CD45RA- effector memory IL-9-producer lymphocytes increased in non 
responder RA patients after branded infliximab exposure, whereas CCR7+, CD45RA+ 
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naïve and CCR7-, CD45+ terminal effector memory Th9 cells, although being more 
represented in RA patients than in healthy subjects, did not vary after drug stimulation.  
   In line with the previous experiment, the exposure to biosimilar infliximab did not 
induce an increase in the percentage of memory Th9 cell in non responder patients.  
 
Conclusions 
   IL-9 levels are increased in RA patients, in whom this cytokine plays indeed a 
crucial role. Th9 cells are the major producers of IL-9, and their prevalence is higher 
in RA patients than in healthy subjects. According to our results, PU.1+, IRF4+ Th9 
cells may be involved in orchestrating the immune response against the epitopes of 
branded infliximab; and this condition could rely on the recall and stimulation of both 
central and effector memory cells. On the other hand, biosimilar infliximab seems not 
able to activate these pools of cells. However, no significant difference was noticed in 
the PU.1+, IRF4+ Th9 cell percentages in Remicade®-responder patients after 
stimulation test either with biosimilar and branded infliximab, proving that in vitro 
both the two drugs seem to have a comparable efficacy.  
   Our results carry a novel point of view in the immunogenicity of anti-TNF agents, 
routinely based on the detection of anti-drug antibodies. However, since actual 
knowledge is still scarce, these data, highlighting a discrepancy between the Th9-
driven immunogenicity of branded and biosimilar infliximab, indeed deserve further 
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Immunogenicity	  of	  biologic	  drugs	  	  
1.1 Biologic drugs: properties, characteristics, beneficial and side effects   
   Biologic agents represent a revolutionary class of drugs, obtained by means of 
genetic engineering, commercially available since latest ‘90s. These drugs may be 
produced using the recombinant DNA technique that allows the introduction of a 
genetic sequence inside the genome of cultured cells, or by the development of 
ibridomes, consisting in murine B lymphocytes that share common aspects with 
neoplastic plasma cells, and are able to produce huge amounts of monoclonal 
antibodies reacting against specific antigens.  
   Specifically biologic drugs may be subdivided into 3 groups: 
1) Proteins, obtained by means of recombinant DNA technique  
2) Monoclonal antibodies, recognizing and neutralizing specific antigens (ab-
ending) 
3) Fusion proteins (cept-ending) that consist in soluble receptors, recognizing 
specific ligandos, joined to the fragment crystallizable region (Fc region) of an 
immunoglobulin G (IgG) 
   The last two classes include nearly the entire category of biologic drugs used for the 
treatment of rheumatic diseases.  
  Indeed the most important advantage in using these drugs is the high specificity in 
recognizing molecules usually involved in the inflammatory cascade, thus preventing 
further repercussions on other cells or organs.  
   Currently, rheumatologists have at disposition for the treatment of rheumatoid 
arthritis (RA) seven biologic drugs against the cytokine Tumor Necrosis Factor-alpha 
(TNFα) and therefore called anti-TNF agents; one directed against the B cells surface 
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antigen CD20; a receptor antagonist of the interleukin (IL)-1; an antagonist of the 
receptor of the IL-6; and a receptor fusion protein displaying a Cytotoxic T 
Lymphocyte Antigen-4 domain activity (CTLA4). 
  In the next years an increase in the availability of biosimilar drugs and drugs with 
other mechanisms of action (e.g. against IL-17) or with different molecular properties 
is expected.  
   These drugs have dramatically changed the prognosis of rheumatic diseases, leading 
to fair rates of clinical remission; however, the occurrence of adverse events such as 
infectious diseases or cancers arises the need for a strict surveillance of the patients 
undergoing this kind of treatment. Furthermore, there is 20-30% likelihood of non-
response either based on a primary (genetic) resistance or on the development of an 
immune response directed against the drugs themselves, which may behave as 
antigens [1]. 
 
1.1.1 Anti-TNF agents 
   Anti-TNF agents include a class of biologic drugs directed against the cytokine 
TNFα and currently licensed for the use in RA, psoriasis and psoriatic arthritis (PSA), 
ankylosing spondylitis (AS) or non radiographic spondyloarthritis (SpA), intestinal 
bowel diseases (IBD), juvenile idiopathic arthritis (JIA) and uveitis. These compounds 
comprehend three entire monoclonal antibodies or moAbs (infliximab; adalimumab; 
golimumab), one fusion receptor protein (etanercept) and a FAB fragment conjugated 
to a pegylated substrate (certolizumab pegol).  
    All these agents share the capability of binding and neutralizing the cytokine TNFα, 
even though some differences occur in the molecular structures, the route and timing 
of administration, the spectrum of action, and the safety profile. TNFα is a cytokine 
notoriously associated to septic shock related to the exposure to lipopolysaccharide 
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(LPS) [2], but it also plays a prominent role in autoimmune diseases. TNFα belongs to 
the large super-family of TNF/TNF receptors (TNFRs) characterized by a trimeric 
structure and participating in the survival and activation of cells belonging to the 
immune system [3].  
   TNFα is mainly synthesized by macrophages and monocytes in trans-membrane 
form (tmTNFα), part of which is then cleaved in soluble form (sTNFα) by a metallo-
protease known as TACE. Both tmTNFα and sTNFα bind two receptors: TNFR1 and 
TNFR2. The first is expressed on almost all cells and mediates proliferative or pro-
apoptotic signals through its TRAF Interaction Domain (TIM) and Death Domain 
(DD); the second, which has been less extensively characterised, is carried by nerve, 
endothelial and immune system cells and, as it does not have a death domain, seems to 
be mainly involved in the proliferative pathway [4,5]. The biological effects of TNFα 
on target cells (ranging from survival to apoptosis) explain many of the biological 
implications of anti-TNF treatment [6]. TNFα induces the activation of neutrophils, 
macrophages, monocytes, chondroclasts, osteoblasts, osteoclasts, synoviocytes, 
hepatic and endothelial cells, thus weaving a complex network that leads to synovial 
membrane hyperplasia, bone destruction and systemic inflammation. Most of these 
effects are induced by TNFα as a ligand, but tmTNF may also act as a receptor and 
carry pro-inflammatory signals inside the cells that bear it, including T cells, 
macrophages and Natural Killer (NK) cells. The individual anti-TNF drugs have 
different biological activities in contrasting the effects of tm and sTNFα. Being 
bivalent moAbs, infliximab, adalimumab and golimumab can bind simultaneously two 
different molecules of TNFα in both monomeric and trimeric form. Moreover, 
together with etanercept, they share a Fc that is responsible for antibody-dependent 
cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), 
which are mediated by monocytes or macrophages and NK cells after interactions 
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between the Fc and Fc receptors (FcRs). At the same time, the interaction with FcRII 
and FcRIII (which recognise very large immune complexes such as those containing 
bivalent moAbs) may also mediate a state of immune tolerance as a result of 
monocyte/macrophage hyper-production of tolerant cytokines, such as IL-10 [7].        
Certolizumab pegol is devoid of a Fc and therefore unable to induce ADCC or CDC; 
however, it has greater avidity for tmTNF than the other anti-TNF agents, and may 
prevent the activation of cells by means of reverse signalling. Some authors have 
demonstrated that the interaction of anti-TNF moAbs with tmTNF may induce 
apoptosis via P53 and P21 activation, or the generation of reactive oxygen species 
(ROS), with golimumab having the weakest activity [8]. Anti-TNF agents can have 
different effects on cytokine production: some studies in vitro have found that the 
production of IL-6, IL-10 and IL-5 is increased in peripheral mononuclear cells 
incubated with infliximab but not with etanercept [9], and a study of RA patients 
found a rebalancing of IL-4 and interferon-gamma (IFNγ) in peripheral blood 
mononuclear cells (PBMCs) after exposure to infliximab [10]. The different biological 
properties of TNF-inhibitors may explain why moAbs seem to be more efficient in 
counteracting granulomatous diseases such as Crohn’s disease or uveitis, and less safe 
during granulomatous infections such as tuberculosis [11,12,13].  
   Due to their mechanism of action, the treatment with anti-TNF agents has been 
mainly associated to the risk of developing opportunistic infections [14]. Another 
infrequent event is represented by the development of anti-nuclear antibodies (ANAs) 
or other autoantibodies [15], which may sometimes be associated with the clinical 
manifestations of connective tissue diseases. It is uncertain the role of anti-TNF agents 
in the induction and progression of cancer [16,17,18], therefore their use is currently 
not recommended in neoplastic patients.  
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1.1.2 Non anti-TNF biologic drugs 
        Beyond TNFα, other pathways are implicated in the inflammatory cascade 
operating in rheumatoid arthritis and have represented, therefore, valid goals for the 
development of biologic agents with a different mechanism of action.  
    This class of drugs includes:  
- Anakinra, a receptor antagonist contrasting the signalling of IL-1, currently 
approved for the treatment of RA and autoinflammatory diseases 
 - Rituximab, a moAb directed against the B cells surface antigen CD20  [19] and 
licensed for the treatment of RA and small vessel vasculitis  
 - Abatacept, a fusion protein containing the CTLA4 domain attached to an IgG1Fc 
[20], that prevent the costimulation of T-lymphocytes and has been licensed for the 
use in RA and JIA patients 
 - Tocilizumab, a moAb targeting IL-6 receptors (IL-6Rs) that has been licensed for 
use patients with moderate to severe RA. 
   Non anti-TNF agents may therefore counteract the inflammatory cascade at various 
steps. Both tocilizumab and rituximab, and indirectly abatacept, may impede the 
activation of B lymphocytes. B cells act either as antigen presenting cells (APCs) and 
effector cells by secreting different cytokines, and thus directing the development of 
final T-helper (Th) phenotypes. B cells progressing to plasma cells can also produce 
antibodies whose biological effects range from antigen neutralisation to the 
activation of other cells through the interaction with FcRs, CDC and ADCC, and 
may favour the formation of immune complexes. This indicates that B lymphocytes 
are involved in almost all of the pathogenic phases of RA. CD20, is a trans-
membrane calcium channel protein, expressed on plasma membranes from the stage 
of pro-B cells to that of mature B cells [21]. By binding CD20, Rituximab induces 
the death of B cells by means of CDC and ADCC, and may also induce apoptosis as 
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a result of an increase in the concentration of intracellular calcium ions and the 
activation of caspases, or alterations in mitochondrial trans-membrane potential and 
the generation of ROS [22].  
   IL-6 is a cytokine with a broad spectrum of action. It directly binds IL-6 receptors 
on myeloid cells, hepatocytes, synoviocytes, endothelial cells and osteoclasts, and 
the soluble form can create a complex with a trans-membrane protein called gp 130 
that is found on the surface of many other cells [23]. By the activation of a complex 
intracellular pathway involving the phosphorylation of many protein kinases, IL-6 
promotes Th2, Th follicular and Th17 lymphocyte survival, enhances the expression 
of adhesion molecules and the production of pro-angiogenic factors by endothelial 
cells, increases the expansion of synoviocytes and osteoclasts, and favours the 
synthesis of antibodies and the differentiation of megakaryocytes. Together with IL-1 
and TNFα, it also significantly contributes to systemic inflammation as a result of the 
hepatic release of many acute-phase proteins, such as C-reactive protein (CRP). 
  The activation of T lymphocytes may be repressed by abatacept. By preventing the 
co-stimulatory mechanisms that occur during the activation of naïve T lymphocytes 
[24], abatacept induces clonal anergy and represses the transcription of genes 
encoding IL-2 and its receptor, CD25, CD68, cyclin D, and various cyclin-dependent 
kinases [25]. Abatacept acts at the beginning of the inflammatory cascade providing 
a negative signal that allows immune tolerance towards self-antigens in peripheral 
lymphoid organs. The CD80-CD86/CD28-CTLA4 complex acts in fact during the 
priming of naïve T cells, whereas other molecules such as ICOS or CD40 may be 
more important in the recall phases [26]. This condition is mirrored by the higher 
disease activity score on 28 joints (DAS28) remission rates in early RA patients than 
in long-lasting ones treated with abatacept for 1 year [27].  CTLA4 may also mediate 
a signal inside cells carrying CD80 or CD86 molecules, the effects of which include 
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the induction of tryptophan metabolism by the enzyme indolamine 2,3 dioxygenase 
(IDO) to the detriment of T cells [28], the reduced expression of adhesion molecules 
by endothelial cells [29], and impaired cytoskeletal organisation in macrophages 
[30]. 
   Efficacy and safety data from registries and randomized controlled trials (RTCs) 
have shown a comparable profile between anti-TNF and non anti-TNF agents, 
although some slight differences may occur regarding the risk of opportunistic 
infections, autoimmune manifestations or cancer risk 
[31,32,33,34,35,36,37,38,39,40,41,42,43].  
 
1.1.3 Biosimilar biologic drugs 
   According to World Health Organisation (WHO) definition, a biosimilar drug 
consists in a “biotherapeutic product that is similar in terms of quality, safety, efficacy 
to an already licensed reference biotherapeutic product” [44]. The use of biosimilar 
drugs has recently gained interest in consideration of the cost-sparing effect (about 20-
30% saved compared to the reference product) and the patent expiry for many of the 
biologic drugs currently used for the treatment of rheumatic diseases. Currently, only 
infliximab (Remicade®) has expired its license, therefore the use of biosimilar drugs 
with the same therapeutic indications of infliximab has been licensed in USA and 
Europe, after successfully passing a careful examination on the comparability of the 
efficacy and safety profile.  
   In fact, before approving the commercialisation of a biosimilar product, the 
European Medicines Agency (EMA) requires a full report on physic-chemical 
characterization, in vitro and in vivo biologic activities of the new compound, and a 
demonstration of comparable efficacy and safety in patient population.  
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   Two RCTs (PLANETRA and PLANETAS) have been conduced respectively on RA 
and AS patients in order to compare infliximab and its biosimilar CT-P13. Both the 
two trials led to the conclusion that biosimilar infliximab shares an overall comparable 
profile with the reference product [45,46]. According to these studies, EMA approved 
the extrapolation of the use of CT-P13 for each clinical indication for which 
infliximab has already been approved. 
 
1.1.4 Recommendations for the use of biologic drugs in rheumatoid arthritis 
   The treatment of RA has been revolutionised since the introduction of biologic drugs 
that allow a fast symptoms remission, prevent disability and radiographic progression 
and ameliorate the prognosis. However, given the availability of several molecules 
with different targets, the current evidences for the best therapeutic strategy is still a 
matter of debate. Indeed RA patients should be early diagnosed and treated in 
accordance with the treat-to-target strategy [47]. The updated 2013 European League 
Against Rheumatism (EULAR) guidelines for the management of RA with synthetic 
and biological disease modifying anti-rheumatic drugs (DMARDs), suggest the use of 
biologic agents after the failure of a previous conventional line, without no preference 
for anti-TNF or non anti-TNF agents abatacept and tocilizumab as first or second line. 
The use of rituximab in first line may be taken in consideration in patients with a 
recent history of lymphoma or tuberculosis, whereas the use of anakinra has not been 
encouraged due to an inferior efficacy profile [48]. The 2015 American College of 
Rheumatology (ACR) guidelines approved the use of both anti-TNF and non anti-TNF 
agents in early (< 6 months) and established RA patients failing a previous 
conventional line, and suggest the swap to a non anti-TNF biologic in patients failing a 
previous anti-TNF agent, either in 2° or in 3° line [49]. Interestingly, both the 
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European and the American guidelines encourage the discontinuation of biologic 
therapies once the remission has been achieved and long maintained.   
 
1.2 Generalities on the immunogenicity of biologic drugs 
   The immunogenicity of a drug consists in the faculty of inducing an immune-
mediated response against the drug itself. This condition is related to the presence of 
epitopes in the molecular structure of the drug carrying an antigenic potential and 
capable, therefore, of activating specific T and B effector responses [15]. The biologic 
MoAbs are synthetized in murine cells and contain some foreign aminoacidic 
sequences that display a high antigenic potential. Therefore, these molecules undergo  
several modifications in order to minimize the antigenic burden due to allotypic 
components. Infliximab and its biosimilar compounds display the highest 
immunogenicity among other anti-rheumatic biologic agents, due to the 25% murine 
components in their structure, that may induce the formation of antibodies against the 
murine complementary and framework regions of the MoAbs [50]. The other biologic 
drugs, despite being modified and humanised, may retain variable percentages of 
immunogenicity, underlining the concept that other factors may influence the 
immunogenicity of a compound.  
   Some of these factors may belong to the patient whereas others depend on the drug 
itself [51].  
   Patients-related factors include the immunologic status, the genetic background, the 
age of the patient, the underlying disease and concomitant medications.  
   The immunologic status conditions the response to an antigen and is often dictated 
by a favourable genetic background and amplified by the activity of the underlying 
disease. Polymorphic variants in the Major Histocompatibility Complex (MHC) may 
influence the presentation of epitopes to T lymphocytes, thus unbalancing the 
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immunologic tolerance. Previous infection in MHC-predisposed patients may trigger a 
cross-reaction with biologic drugs. Andrick et al. have supposed a molecular mimicry 
between the influenza hemoagglutinin antigen and anti-TNF moAbs in HLA-DR1 RA 
patients [52].  
   The age of the patient may also affect the immune response towards antigens, 
including drugs. Paediatric patients affected by JIA have a five-fold higher risk of 
developing anti-drug antibodies (ADAs) against infliximab compared to RA adult 
patients receiving intravenous (i.v.) infliximab 3 mg/kg plus methotrexate, and the 
latter patients have a two-fold higher risk of developing ADAs when compared to 
psoriatic arthritis patients receiving i.v. infliximab 5 mg/kg. These data show that the 
underlying rheumatic disease as well as the administered dose may also affect the 
immune response to a drug.  
   The concomitant use of methotrexate or other immunosuppressive drugs reduces the 
risk of ADAs. In a controlled randomized study on Crohn’s disease patients, the 
premedication with i.v. hydrocortisone before the first infusion of infliximab 
approximately reduced the risk of ADAs from 42% to 26%, ameliorating also the 
clinical outcome. Similarly, in those patients, the concomitant use of azathioprine may 
reduce the formation of ADAs.  However, in RA, steroid premedication and the use of 
other immunosuppressive drugs than methotrexate seem to be not successful in 
preventing immunogenicity [53].   
   The drug-related factors include the molecular structure, the route of delivery, the 
interval of administration, the exposure time, the cross-reactivity with previously used 
drugs, and the post-translational changes.  
   MoAbs are usually more immunogenic than receptor proteins. MoAbs directed 
against antigens sited on the cell surface are more immunogenic than those 
	  17	  
recognizing a soluble ligando, perhaps due to the subsequent process of internalization 
of the complex and presentation to target cells.  
   The immunogenicity of a compound largely depends on the percentage of allotypic 
sequences on its molecular structure. Therefore, infliximab displays the highest 
immunogenicity among biologic drugs, as the murine sequences account for the 25% 
of the entire molecule. However, humanised moAbs, such as adalimumab, may have a 
surprisingly high immunogenicity, probably related to the post-translational 
modifications (glycosylation, deamidation, oxidation, formation of disulphide bridges, 
and protein folding) or to the formation of anti-idiotype antibodies. During the 
humanisation process, in fact, the complementarity determining regions (CDRs) of the 
variable framework maintain the original murine aminoacidic region and may 
represent a source of epitopes for CD4+ T cells [54].  
   The route of delivery and the interval between two consecutive administrations 
represent two other important factors that can influence the immunogenicity of a drug. 
Subcutaneous administration may paradoxically arise a higher amount of immune 
reject due to the abundance of antigen-presenting cells in the site of delivery. The 
intermittent exposure, as well as a long-term exposure, represents also an aggravating 
factor for the development of ADAs. 
   Cross-reactivity with previous drugs has gained a noteworthy interest in the switch 
among similar biologic drugs, like anti-TNF agents. There are no evidences that anti-
TNF drugs belonging to different classes have cross-reactive epitopes [50]. On the 
contrary, it has been demonstrated that biosimilar compounds of infliximab may cross-
react with the originator drug [55]. However, the immunogenicity of a biosimilar drug 
may not match entirely that of the original drug, mostly due to differences in post-
translational modifications [56].   
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   Finally, the assay chosen for the detection of ADAs may influence the amount of 
antibodies detected, been radio immunoprecipitation assay (RIA) a more robust but 
also a more expensive test than enzyme linked immunosorbent assay (ELISA). ADAs 
may belong to different isotypic classes, including IgE or IgM as demonstrated by 
Vultaggio et al. [57]. Moreover, the concentration of ADAs may fluctuate according to 
the time of serum collection. A specific ADAs limen in predicting the tolerability of 
infliximab is still controversial, although Baert et al. postulated that a serum 
concentration ≥ 8 µg/mL is associated with 2.4 RR of developing an adverse event 
[58,59]. Therefore, the serum concentration of the free drug, usually lower in patients 
developing ADAs towards a biologic treatment, has replaced the measurement of 
ADAs.  
   Furthermore, beyond the stimulation of B cells and the subsequent production of 
ADAs, the activation of other immunologic pathways in response to a biologic drug 
may account for an alternative point of view of the immunogenicity phenomenon. 
There are some reports in literature that focus on the activation of CD4+, CD8+ T 
cells, NK cells and monocytes in the skin biopsy specimens of rheumatic patients 
developing a cutaneous exanthema following the administration of i.v. infliximab [60]. 
In a recent study, we demonstrated that the addition in vitro of 50 µg/mL infliximab to 
PBMCs cultures from RA patients who had or not responded to infliximab, altered the 
balance Th1-Th17/T regulatory (Treg) lymphocytes in favour of Th1-Th17 cells in 
non responder patients and of Treg lymphocytes in responder ones [61]. Further 
studies are indeed requested to elucidate all the possible immunologic pathways, along 
with the related different clinical implications, involved in the immune response 




1.2.1 The immunogenicity of biosimilar drugs 
   According to WHO definition a biosimilar drug should have a comparable safety 
profile to the reference product (RP).  
    Being branded infliximab and CT-P13 biosimilar but not identical, many in vitro 
tests, such as antibody conformational assays, have been performed in order to assess 
and fully elucidate their immunogenicity. These experiments have shown that the 
immune-dominant structures are similar between the two compounds. The two RCTs 
PLANETRA and PLANETAS, respectively on RA and AS patients, have 
demonstrated a comparable percentage of anti-drug antibodies (ADAs), measured by 
means of electrochemiluminescence, both in the reference product and biosimilar arm 
(respectively 52.3% for CT-P13 and 49.5% for RP in RA, and 22.9% for CT-P13 and 
26.7% for RP in SA) at week 54, and similar percentages were also maintained after 
switching from RP to CT-P13 in the extension phase at week 102 [45,46]. Similar 
results have been obtained in spontaneous trials on IBD as well as SpA patients, unless 
all these studies are characterized by a short period of observation [62,63,64]. Ben-
Horin et al. have demonstrated that ADAs against infliximab from sera of IBD 
patients cross-reacted with CT-P13 but not with adalimumab in vitro [55]. Moreover, 
the authors found that in basal and unstimulated conditions, CT-P13 elicited a higher 
background signal than RP that became not significant only after monomer 
purification.  
   Original infliximab and biosimilar CT-P13 have a slightly different molecular 
structure. According to EMA report [65], CT-P13 shows less C-terminal lysine with a 
overall less basic charge [66], a higher amount of aggregates (however not exceeding 
1% of the compound) and a higher amount of not-assembled forms than infliximab 
originator; furthermore, some differences in post-translational modifications such as a 
higher degree in oxidised and fucosylated variants have also been described. The 
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higher degree in fucosylation of CT-P13 has been particularly focused, according to 
the well-known interference of fucosyl residuals sited in the Fc with the FcγR 
(especially FCγRIIIa and FCγRIIIb) binding [67]. This condition, although apparently 
not affecting immunogenicity, may reduce the ADCC properties of the moAbs so that 
recently controlled fucosylation has become a goal in the field of onco-immunology in 
order to obtain the highest degree of ADCC with the lowest drug concentration [68]. 
EMA report assures that NK-dependent ADCC reactions, although seeming impaired 
in vitro, are restored in vivo by the coexistence of other serum factors. However 
fucosylation of Fc may also induce a change in steric conformation and in charge. It 
has been demonstrated, in fact, that infliximab displays at least 2 B cell epitopes in the 
Fc containing a glycosylated pattern [69]. Therefore, post-translational modifications 
















- Chapter 2 - 
The pool of T helper lymphocytes and T helper 9 cells 
 
2.1 Generality on T helper lymphocytes and their role in rheumatoid arthritis 
   CD4+ T helper lymphocytes orchestrate the adaptive immune response to 
pathogens. Naïve CD4+ T cells interact by means of T Cell Receptors (TCRs) with 
APCs and are activated by costimulatory receptors and cytokines. According to the 
cytokine milieu, these cells may differentiate into many subsets. Originally it was 
supposed that CD4+ T cells could give raise to two different pools, named Th1 and 
Th2, the first involved in the defence against intracellular pathogens and the latter 
against extracellular ones. Nowadays it is well known that Th pools include other 
subsets, displaying both pro-inflammatory and anti-inflammatory properties [70].  
   Th1, Th2, Th17, Treg, Th9, Th22 and Th follicular cells represent CD4+ Th 
lymphocytes with different phenotypes, responsible for different immune responses.  
    Th1 lymphocytes differentiate in presence of IL-12, express the transcriptional 
factors T-bet, STAT1 and STAT4, and produce IFNγ,  IL-2 and TNFα.  
    Th2 lymphocytes differentiate in presence of IL-4, express the transcriptional 
factors STAT6 and GATA-3 and produce IL-4, IL-5, IL-10 and IL-13.  
    Th17 cells require IL-6, Transforming Growth Factor-beta (TGFβ), IL-21 and IL-
23 for their differentiation, express the transcriptional factor RORγt and produce 
mainly IL-17. This subset is highly expanded during autoimmune diseases and 
actively contributes to their pathogenesis. 
  Treg cells develop in response to TGFβ, express the transcriptional factor FOXp3 
and produce IL-10 or TGFβ, repressing the inflammatory cascade and restoring the 
peripheral tolerance.  
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   Th22 cells, developing following the stimulation with IL-6 and TNFα, represent a 
recently discovered subset that produces IL-22, IL-10 and TNFα with detrimental or 
favourable effects on inflammation. They express the transcriptional factor AHR and 
several fibroblast growth factors (FGFs).  
   Th follicular cells may develop from Th1, Th2, Th17 or Treg cells, express Bcl-6 
and secrete IL-4 or IL-17 in the B-cell follicle, thus favouring the maturation of 
plasma cells and the production of autoantibodies.  
   Finally, Th9 lymphocytes designate another recently studied T helper subset, 
whose development is favoured by the combined action of TGFβ and IL-4. These 
cells express the transcriptional factors PU.1 and IRF4 and mainly synthesize IL-9. 
Th9 lymphocytes have been recently associated to the pathogenesis of rheumatic 
diseases. 
   T helper cells have a high plasticity and may differentiate from one subset to 
another one according to the cytokine milieu [71]. For example, Th1 cells may 
secrete IL-10 and Th2 cells may be induced to produce IFNγ or IL-9. Th17 cells may 
synthesize IL-4 and Treg cells may produce IL-17. These cells are therefore capable 
to reprogram their transcriptional factors to those owned at a naïve stage and re-
differentiate into other subsets, prevalently during the early phase of differentiation.  
 
2.2 Modification of T helper subsets according to concomitant treatment 
   The use of immunosuppressive drugs may influence the populations of CD4+ Th 
cells. Indeed many studies have reported an increased percentage of Th17 
lymphocytes in the serum, synovial fluid and synovial membrane of patients with RA.      
Similarly, an increased number of Treg cells expressing both CD25 and FOXp3 has 
been reported in the synovial fluid and synovial membrane of patients with RA where 
they could counteract the inflammatory cascade [72]. Moreover, some authors have 
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described hybrid pools of CD4+ T cells, expressing both IL-17 and FOXp3 in the 
serum and synovial tissues of RA patients, underlining the concept that Treg cells may 
differentiate in a second moment into effector cells with perhaps more pathogenic 
properties than primary Th17 lymphocytes [73].  
     Treatment may influence the amount of T effector and regulatory cells. The use of 
corticosteroids in RA, for example, seems to reduce the Th2 responses while does not 
affect the Th17 ones, perhaps due to a multi-drug resistance [72]. Although 
methotrexate seems to have no effect in healthy subjects, in RA patients it may down-
regulate Th17 responses and up-regulate Treg ones. Methotrexate reduces the 
transcription of IL-17 messenger RNA from PBMCs of RA patients in a dose-
dependent manner, although it does not seem to influence the percentage of IL17+, 
CD4+ T cells [74]. The concomitant use of methotrexate and steroids in an in vivo 
experiment on RA patients reduced the percentage of Th17 cells sorted as CCR4+, 
CCR6+, CD4+ lymphocytes [75]. Similarly, hydroxychloroquine (HCQ) may interfere 
with the production of some cytokines such as IL-17, IL-6 and IL-22. Oh et al. have 
reported that in healthy subjects the use of sulphasalazine and leflunomide may reduce 
the expression of FOXp3 in Treg cells, repressing the inhibitory properties on CD25-, 
CD4+ T effector lymphocytes, without affecting their whole number, whereas 
methotrexate and infliximab do not [76]. On the contrary in RA patients other authors 
have reported that infliximab induces an increase in Treg cells, while reducing Th17 
cells, especially in responder patients. The neutralisation of TNFα may variously 
affect the Th subsets. TNFα favours the development of Th17 lymphocytes and some 
in vitro experiments with infliximab have proved efficacious in reducing Th17 effector 
differentiation [77]. However, in a study on healthy subjects the administration of i.v. 
infliximab 10 µg/mL depressed the production of IFNγ by Th1 cells, with minor 
effects on Th17 cells [78]. In RA patients infliximab may have an opposite effect, 
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increasing the ratio IFNγ/IL-4 in responders and depressing Th2 responses [10]. In AS 
patients, following a 6 week treatment with infliximab, some authors have observed a 
discrepancy between the improved clinical outcomes and the T cell subsets, with a 
persistent prevalence of Th2 and Th17 lymphocytes at 6 weeks of therapy [79]. 
Contradictory results have reported with adalimumab. A recent work on psoriatic 
patients has reported a reduced concentration of circulating Th1, Th17 and Th22 
lymphocytes following a 12 week treatment with adalimumab [80]. Etanercept seems 
not to influence the percentage of Th17 lymphocytes with contrasting results on 
CD4+, CD25+, FOXp3+ T cells. According to some authors, etanercept but not 
adalimumab nor infliximab normalizes the percentage of Th2 cells after 4 weeks of 
treatment [75]. No certain results are available on abatacept either regarding Th17 or 
Treg cells. In line with other conventional and biologic drugs, tocilizumab reduces the 
number of Th17 cells and induces an increase in Treg cells.  
 
2.3 Th9 lymphocytes 
   Th9 cell, discovered in 2008 by Veldhoen et al., are a T helper cell subset 
developing from primary naïve T helper lymphocytes or from primed T helper 2 
lymphocytes in presence of IL-4, TGFβ, OX40 and PU-1 [81]. The main cytokine 
secreted is IL-9, but, in vitro, these cells may also produce IL-10, IL-17, IL-21 and 
IL-22 [82].  It has been demonstrated that Th2 cells, Th17 cells, Treg cells, innate 
lymphoid cells (ILC), mast cells, NKs are capable of releasing large amount of IL-9 
[83]. However, Th9 cells are a distinct class of CD4+ T lymphocytes, identified by a 
peculiar set of transcriptional factors (PU.1, IRF4). The role played by Th9 cells has 
been investigated in vitro and in vivo. Th9 lymphocytes seem to be involved in the 
immunological responses underlying parasitic infections as well as allergic diseases 
[84,85]. A consistent number of reports has evidenced that these cells are highly 
	  25	  
represented in the airways of asthmatic subjects and in the skin of people suffering 
from atopic dermatitis [86,87]. Recent studies on melanoma carcinogenesis have 
evidenced that Th9 lymphocytes enhance the intra-tumor expression of chemokines 
and their receptors such as CCL20 and CCR6, thus promoting the local recruitment 
of dendritic cells and anti-tumor CD8+ T lymphocytes [88].  
   The role of Th9 cells in rheumatic diseases is less characterized. According to 
some studies, IL-9 may contemporarily favour the differentiation of Th17, acting like 
IL-6 or IL-21 in the presence of TGFβ, and inhibit the apoptosis of Treg cells, by 
enhancing the expression of STAT5 (Fig.1). Mice knock-out for IL-9R gene develop 
a more aggressive form of experimental autoimmune encephalomyelitis when 
compared to wild types, mainly due to an over-expansion of the Th1 lineage [89].      
Similar results have been obtained in a recent report that analysed the cytokine 
interplay in human skin samples and murine models of atopic dermatitis, finding an 
indirect regulation of IL-9 on IFNγ expression [90]. On the other hand, IL-23 and IL-
21 represent inhibiting cytokines for the development of Th9 lineage. IL-9 mRNA 
and IL-9R have been found significantly increased in gut specimens from ulcerative 
colitis patients, where this cytokine may activate neutrophils and epithelial cells, 
delaying ulcers healing [91]. In the gut, Th9 cells are involved in the defence against 
parasitic infections and an increase in this T helper subset may represent a link 
between dysbiosis and autoimmune inflammatory bowel diseases [84]. One study on 
connective tissue diseases reported increased serum levels of IL-9 in systemic 
sclerosis but not in systemic lupus erythematosus or dermatomyositis, being 
inversely correlated with the degree of lung fibrosis [92]. This result may be 
interpreted in the light of the pleiotropic effects of IL-9, promoting at the same time 
the expansion of Treg and Th17 lymphocytes [93].  
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   To our knowledge, there are actually few studies on the involvement of IL-9 and 
IL-9 producer cells in RA. One study analysed the serum cytokine profile by means 
of multiple suspension array in six RA patients undergoing a treatment with 
rituximab after failing a previous therapy line with infliximab. The authors found 
increased levels of IL-9 at baseline and at follow-up times in responder patients and 
concluded that IL-9 may be considered as a predictive marker of response to 
rituximab [ 94 ]. Another study on 44 subjects showed an increased serum 
concentration of IL-9 in first-degree relatives of RA patients, which was associated 
to a higher ratio of autoantibody positivity, such as rheumatoid factor (RF) or anti-
citrullinated peptide antibodies (ACPAs) [95]. A recent report on RA, PSA and 
osteoarthritis patients showed an augmented concentration of IL-9 in blood and 
synovial fluid of RA and PSA subjects than in osteoarthritis ones. Furthermore, the 
treatment of magnetically sorted synovial and blood CD3+T cells with recombinant 
IL-9 induced their expansion only in RA and PSA samples, underlining the hyper-
expression of IL-9R on cells coming from patients suffering from autoimmune 
arthritis [96]. Finally, an elegant histological study on synovial membrane biopsies 
from RA patients, evidenced an augmented expression of Th9 lymphocytes in the 
most aggressive forms of disease and an association between these cells and the 




	  From Talotta R. et al. Reumatismo 2016 
Fig.1. The network of IL-9 and IL-9 producing cells. Th9 lymphocytes are 
induced following the stimulation with IL-4, TGFβ, IL-1, IL-2 and the 
interaction of TCR, OX40 and CD28 with their ligandos; on the contrary, 
IFNγ, IL-21 and IL-23 inhibit their differentiation. Th9 cells express specific 
transcriptional factors (PU.1 and IRF4) that favour the activation of NFkB. 
Beyond Th9 lymphocytes, Th17 cells, T regulatory cells, eosinophils, mast cells, 
innate lymphoid cells (ILCs) and polymorphonucleates (PMN) may produce IL-
9. IL-9 interacts with its receptor (IL-9R), composed by a specific α- and a 
common γ-chain, thus activating an intracellular pathway that promotes the 
transcription of specific genes responsible for the survival of either Th17 









- Chapter 3- 
Th9 lymphocytes in rheumatoid arthritis: focus on immunogenicity during the 




3.1 Rationale   
    Since Th9 lymphocytes have been associated to the pathogenesis of RA and other 
autoimmune diseases, we wondered whether these cells might also be involved in the 
immune response against biologic drugs. This consideration arose from an our previous 
study demonstrating that infliximab may repress or induce the proliferation of Th17 and 
Th1 lymphocytes when added in vitro to PBMCs from RA patients respectively responding 
or not to the therapy [61]. Along with these results, we also observed in the same 
experiment an overgrowth of CD25+, FOXp3+, CD4+ Treg cells in RA patients who 
achieved a good response under infliximab treatment, but not in those who had discontinued 
the treatment, where these cells were on the contrary reduced following the in vitro addition 
of infliximab. Th9 cells may be considered as connectors between autoimmunity and 
immune-tolerance, favouring at the same time Th17 and Treg responses. Th9 lymphocytes 
are associated to the production of antibodies and, in RA, to the titres of ACPAs and RF. 
The immunogenicity of a drug is mostly based on the production of antibodies against the 
epitopes of the drug itself. Accordingly, Th9 lymphocytes may help B cells in the 
production of ADAs, or tune Th17 or Treg drug-specific responses. To our knowledge, no 
study has still attempted to elucidate the role of Th9 cells in the immunogenicity of biologic 
drugs used for the treatment of RA. 
   According to the molecular structure and the high number of immunogenic epitopes, the 
i.v. anti-TNF moAb infliximab was considered the most suitable candidate for our intent 
and therefore chosen as both original and biosimilar product for the experiment.   
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3.2 Aim of the study 
The aim of this study can be subdivided into the following objectives: 
1) Primary objective: to evaluate the prevalence of Th9 lymphocytes in the peripheral 
blood of RA patients, assigned or not to an immunosuppressant treatment (including 
conventional drugs and infliximab), and to assess the immunogenicity of infliximab by 
detecting changes in Th9 percentages following an in vitro stimulation assay. 
2) Secondary objective: to compare the Th9-related immunogenicity of infliximab 
originator and its biosimilar compound (Remsima®). Other secondary endpoints 
included the association between the variation in the Th9 cell percentage and the 
demographic and clinimetric features of the cohort, the use of concomitant drugs or the 




   We enrolled 55 consecutive RA outpatients according to ACR/EULAR 2010 criteria [98]. 
Patients were recruited from another previous study aiming to explore the Th1/Th17-driven 
immunogenicity of infliximab (Remicade®) [61]. This cohort included 15 subjects affected 
by RA not concurrently treated with immunosuppressive drugs, 20 patients successfully 
treated with branded infliximab, 20 patients who had switched or swapped from branded 
infliximab to other biologic drugs due to adverse events or inefficacy, and a matched control 
group of 10 healthy subjects. Patients and controls were consecutively enrolled for six 
months from June 2013 to December 2013.  
   Concurrent infections, atopic dermatitis, haematological disorders, a concomitant or 
recent treatment with leflunomide or cyclosporine, and vaccinations in the previous 2 
months represented exclusion criteria, since these drugs or medical conditions could 
variously affect the Th cell pool [99,100,101,102,103].  
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The protocol was approved by our Local Ethic Committee and conduced in accordance with 
the Declaration of Helsinki. An informed consent was obtained from each participant before 
entering the study. 
 
3.3.2 Laboratory  
   After giving an informed consent, 18 mL peripheral blood from each subject was 
collected into Vacutainer tubes containing EDTA (Becton Dickinson; Rutherford, NJ, 
USA). PBMCs were isolated by centrifugation on lymphocyte separation medium 
(Cedarlane Laboratories, Burlington, NC, USA). The number and viability of PBMCs were 
determined by an automatic cell counter, ADAM-MC (Digital-Bio, NanoEnTek Inc., 
Corea). PBMC viability was typically > 98%. Cell cultures were performed in RPMI 1640 
plus Penicillin, Streptomycin, L-Glutamine and 10% pooled Human AB Serum (all from 
Euroclone, Siziano, Italy). PBMCs, at a concentration of 1×106 cells/mL were incubated for 
18 hours with culture medium alone or in the presence of 50 µg/mL infliximab (Remicade®, 
Janssen Biologics, Leiden, Netherlands) or its biosimilar (Remsima®, Celltrion Healthcare, 
Budapest, Hungary), 50 µg/mL Human IgG1kappa (Sigma-Aldrich, Saint Louis, Mo, USA) 
or 50 µg/mL recombinant Human IgG Fc (R&D Systems, Minneapolis, MN, USA). PWM 
(Lectin from Phytolacca Americana; 1 µg/mL Sigma-Aldrich), was used as a positive 
control to evaluate the responsiveness of PBMCs. To facilitate co-stimulation, 1 µg/mL 
anti-human CD28 (R&D Systems, Minneapolis, MN, USA) was added to the cell cultures. 
Brefeldin A (10 µg/mL; Sigma-Aldrich) was added after the first three hours in order to 
inhibit cytokine secretion.  
   The percentage of Th9 lymphocytes was determined by flow cytometric analysis. In a 
former analysis, Th9 lymphocytes were identified as IFNγ-, IL-4-, IL-17-, IL-9 secreting 
CD4+ T cells [104]. In a second time, for a more precise identification of the Th9 subset, 
the co-expression of IL-9 and transcriptional factors PU.1 and IRF4 (which are required for 
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IL-9 production and Th9 development) was assessed. The percentage of OX40 expressing, 
IL-9 secreting CD4+ T cells was measured as well. IL-9 production by naïve CD4+ T 
lymphocytes (CCR7+, CD45RA+), central memory CD4+ T lymphocytes (CCR7+,  
CD45RA-), effector memory CD4+ T lymphocytes (CCR7-, CD45RA-), and terminal 
effector memory (TEMRA) CD4+ T lymphocytes (CCR7-, CD45RA+) was also evaluated. 
A concentration of infliximab of 50 µg/mL was chosen after setting a titration test with 
increasing concentrations of the drug and on the basis of the infliximab median serum 
concentrations one hour after infusion (peak serum concentration: 39.9-219.1 µg) [105]. The 
following antihuman monoclonal antibodies (mAbs) were used: CD4 PE-Cy7, IFNγ FITC 
and CD45RA FITC (Beckman Coulter Milan, Italy); IL17 A PerCP-Cy5.5 (Biolegend, San 
Diego, CA, USA); IRF4 PerCP-eFluor® and CD134 (OX40 FITC) (eBioscience, Diego, 
CA, USA); IL-9 APC, IL-4 PE, CCR7 PE, and PU.1 PE (R&D Systems). To evaluate the 
percentage of IL-9 secreting-PU.1 and IRF4 expressing-CD4+ T lymphocytes, PBMCs 
were incubated 15 minutes with the mAbs for the detection of cell surface antigens. Then 
cells were permeabilized 30 minutes at 4 °C with the Fixation/Permeabilization buffer 
(eBiosciences), and further stained for 30 minutes at 4°C with the antibodies for the 
detection of intracellular transcription factors and IL-9. For the evaluation of IL-9 
production by naive and memory CD4+ T cells, PBMCs were incubated 15 minutes at RT 
with the mAbs for the detection of cell surface antigens and fixed with 1% PFA 15 minutes 
at 4 °C. Then cells were permeabilized with Saponin (Sigma) and stained with the 
antibodies for the detection of intracellular cytokines. Following a 45-minute incubation in 
ice, the cells were fixed with 1% PFA. Lymphocyte population was gated based on the basis 
of forward and side scatter properties, and further gated for CD4 expression; at least 20,000 
events were acquired within the CD4 gate. The samples were acquired using a Gallios flow 
cytometer and data were analysed using Kaluza software (both Beckman Coulter).  
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3.3.3 Statistical analysis  
As data were normally distributed, procedures were based on parametric analyses. 
Comparisons between the different groups were performed using unpaired Student’s T Test 
for unequal variances with a two tailed P value. A multivariate analysis was carried to detect 
any interference of demographic characteristics and therapeutic regimens on Th9 
percentages. Significance was set at P <0.05. Statistical analysis was performed using 
GraphPad Prism Software (GraphPad Software, San Diego, CA, USA) and SPSS version 
24.0 (International Business Machines Corporation, New York, NY, USA).    
 
3.4 Results 
     3.4.1 Baseline demographic and clinical assessment  
      In the cohort of drug-naïve RA patients (14 Caucasian subjects and 1 Chinese subject), 12 
were females, mean age ±	 standard deviation (SD) at the time of enrolment was 54.8 ±16.2 
years, mean disease duration ±	 SD was 2.3 ± 3.9 years, ACPAs were detected in 5 patients, 
FR in 7 patients and ANAs in 2 patients. At the time of enrolment mean ±	 SD CRP-DAS28 
was 4.65 ±1.0. All these patients were taking anti-inflammatory and analgesic drugs at need. 
 In the cohort of infliximab-good responder RA patients (19 Caucasian subjects and 1 
Hispanic subject), 16 were females, mean age at the time of enrolment was 61.3 ± 12.2 
years, mean disease duration 13.4 ± 7.2 years, ACPAs were positive in 15 patients, FR in 11 
patients and ANAs in 12 patients. Anti-double stranded DNA (dsDNA), anticardiolipin 
(ACLAs) and anti-extractable nuclear antigen antibodies (ENAs) were detected respectively 
in 3, 1 and 1 patient. Patients have been treated with infliximab (Remicade®) for a mean ± 
SD of 8.3 ± 3.9 years, maintaining a good control on RA activity (mean ±	 SD CRP-DAS28 
at the time of blood sampling 2.5 ±1.0). Concomitant medications consisted in prednisone 
(2.5-10 mg/day), methotrexate (5-15 mg/week) and hydroxychloroquine (200-400 mg/day) 
respectively in 8, 20, 3 patients.  
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 In the cohort of infliximab-non responder RA patients (19 Caucasian subjects, 1 Indian 
subject) 15 were females, mean age at the time of enrolment was 57.0 ± 12.2	  years, mean 
disease duration 18.1 ± 9.5 years, ACPAs were positive in 15 patients, FR in 15 patients and 
ANAs in 17 patients. Anti-dsDNA, ACLAs and anti-ENAs were detected respectively in 2, 
3 and 2 patients. At the time of enrolment 13 patients were treated with i.v. abatacept 10 
mg/kg every 4 weeks, 5 patients with i.v. tocilizumab 8 mg/kg every 4 weeks, 1 patient with 
s.c. etanercept 50 mg once a week, and 1 patient with s.c. certolizumab pegol 200 mg every 
other week, as second (8 patients), third (8 patients) or fourth (4 patients) biologic line.    
Patients had been treated with infliximab (Remicade®) for a mean ± SD of 2.4 ± 1.9 years, 
having discontinued the drug since a mean ± SD of 8.0 ± 2.5 years due to inefficacy (11 
cases) or adverse events (mostly allergic or infusion reactions, 9 cases). Mean ± SD CRP-
DAS28 at the time of enrolment was 2.9 ± 0.8. Concomitant conventional drugs included 
prednisone (2.5-10 mg/day) in 14 cases, methotrexate (5-15 mg/week) in 9 cases and 
hydroxychloroquine (200-400 mg/day) in 5 cases.  












Variables Healthy controls 
Treatment-
naïve  
RA patients  
RA patients 
responding to IFX  
RA patients not 
responding to IFX 
     
No. 10 15 20 20 
Mean age + SD, years  43.9 ± 8.3 54.8 ±16.2 61.3 ± 12.2 57.0 ± 12.2 
Mean disease duration + 
SD, years  
/ 2.3 ± 3.9 13.4 ± 7.2 18.1 ± 9.5 
F/M 4/6 12/3 16/4 15/5 
ACPA + / 5 15 15 
RF + / 7 11 15 
ANA + / 2 12 17 
Anti-dsDNA Ab+ / 0 3 2 
Anti-ENA Ab+ / 0 1 3 
ACLA/LAC + / 0 1 2 
Prednisone 
(2.5-10 mg/day) 
/ / 8 14 
Methotrexate 
(5-15 mg/week) 
/ / 20 9 
Hydroxychloroquine  
(200-400 mg/day) 
/ / 3 5 
NSAIDs / 14 as needed as needed 
        Table 1. Demographic characteristics of the population included in the study. RA: 
rheumatoid arthritis; IFX: infliximab; SD:  standard deviation: F: females; M: males; 
ACPA: anti-citrullinated-protein antibodies; RF: rheumatoid factor; ANA: anti-nuclear 
antibodies; anti-dsDNA: anti-double stranded DNA antibodies; anti-ENA: anti-
extractable nuclear antigen antibodies; ACLA: anticardiolipin antibodies; LAC: lupus 
anticoagulant; NSAIDs: non-steroidal anti-inflammatory drugs.  
 
   3.4.2  Th9 pool at baseline 
   We conducted two separate experiments for the evaluation of Th9 cells. According to 
Schlapbach et al. [104], Th9 cells were initially isolated as IFNγ-, IL-4-, IL-17-, IL-9-
secreting CD4+ T lymphocytes. At baseline, this pool was mostly increased in drug-naïve 
RA patients than in the other groups, with a more pronounced difference when compared 
to healthy controls (p<0.01) than to the group of infliximab responders (p<0.05); fig. 2.  
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   In a second part of the experiment, we aimed to select Th9 cells according to the 
lineage-specific transcriptional factors since other immune cells may produce IL-9. To 
increase the specificity of our analysis we decided to evaluate PU.1 and IRF4, that 
represent the transcriptional factors associated with the Th9 pool; moreover, the 
costimulatory molecule OX-40, which could selectively drive the Th differentiation 
toward a Th9 phenotype while repressing both Treg and Th17 cells development [106], 
was considered in a separate experiment.  
   At baseline, the percentage of IFNγ-, IL-4-, IL-17-, IL-9+, CD4+ Th lymphocytes was 
significantly concordant with that of IL-9+, PU.1+, IRF4+, CD4+ Th cells (p=0.01). 
When identified by the expression of PU.1 and IRF4, Th9 cells were increased in drug-
naïve patients compared to healthy controls and infliximab responder patients (p<0.01); 
fig.6. When sorting Th9 cells according to the expression of the costimulatory marker 
OX40, we found that OX40+ IL9-producing CD4+ T cells were increased in the group of 
drug-naïve RA patients, infliximab-responder and non responder patients compared to 
healthy controls; fig. 11.  
  The higher frequency of Th9 cells in RA patients was not associated with higher levels 
of ANAs or other autoantibody subsets, the duration of the disease, the CRP-DAS28 
score at the enrolment time, neither to the reason of infliximab discontinuation or the 
number of previous biologic drugs administered to the non responder patients.  Moreover, 
a multivariate analysis did not evidence a significant influence of concomitant 
conventional or biological treatment on Th9 percentages at baseline, although the 
heterogeneity of biological therapies and the limited number of cases could have indeed 
represented a bias in the statistical evaluation.  
    In conclusion, either evaluated by the solely production of IL-9 or by the concomitant 
expression of transcriptional or costimulatory factors, Th9 cells were mostly increased in 
unstimulated conditions in untreated RA patients with the highest difference when 
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compared to healthy controls than to the other RA groups. These results highlight that the 
activation of Th9 cells is a distinctive character of RA and may be restored by the 
concomitant treatments. 
 
3.4.3 Effects of infliximab (Remicade®) on T helper 9 pool 
    The stimulation of IFNγ-, IL-4-, IL-17-, IL-9-secreting CD4+ T cells with 50 µg/mL 
original infliximab did not induce a variation in the percentage of these cells in any of the 
group of patients and controls, fig.2. These provisional results have been recently 
published [107]. On the other hand, PU.1+, IRF4+ Th9 cells increased following the 
stimulation with branded infliximab only in the group of non responder patients, fig.3.  
This different behaviour may be related to the heterogeneity of IL-9 producing CD4+ 
cells, which may include at some extent also regulatory cells.  When sorted for specific 
transcriptional factors, Th9 cells were distinguished from other T cell subsets and this 
may account for the discrepancy in the results. No differences before and after infliximab 
exposure were noticed among OX40+, IL-9+, CD4+ T cells (fig.11) and these results may 
be explained in light of the widespread expression of OX40 on Th cell pool [106]. 
   We further wondered whether Th9 lymphocytes could be activated following a specific 
stimulus on Th memory cells from patient who had discontinued the treatment in the past 
for inefficacy or an adverse event. Following an antigenic stimulation, in fact, central 
memory CCR7+, CD45RA- T cells may migrate from lymph nodes to peripheral tissues, 
lose the molecule CCR7 and transform into CCR7-, CD45RA- effector memory T cells 
that display immediate effector functions [108,109]. Furthermore, in case of a protract 
low-dose antigen stimulation, these cells may be able to re-express the molecule 
CD45RA and acquire surveillance functions with less pronounced effector properties 
(TEMRA).  Therefore, we subdivided IL-9+, CD4+ T cells according to the expression of 
the surface molecules CCR7 and CD45RA that allow the discernment among naïve, 
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central memory, effector memory and TEMRA cells. All these pools of cells were 
increased in untreated RA patients compared to the other groups. Following the addition 
of infliximab, IL-9+, CCR7+, CD45– central memory cells and IL-9+, CCR7-, CD45– 
effector memory cells but not naïve Th9 cells were increased only in the group of non 
responder patients, underlining that this pool of cells may account for the modification in 
PU.1+, IRF4+, IL9+, CD4+ T cell percentage in the previous experiment; figg.4,5,8,9. 
On the contrary, the percentage of TEMRA lymphocytes did not vary, due presumably to 
the scarce proliferative activity that characterizes this pool of cells; fig. 10.  
 
3.4.4 Remicade® versus Remsima® effects on T helper 9 pool 
 We repeated the same experiment replacing the branded drug with biosimilar compound 
CT-P13 (Remsima®). In this case we directly evaluated the pool of PU.1+, IRF4+ Th9 
cells, being the transcriptional markers more specific than the secreted cytokines for the 
determination of the Th9 lineage. Like the experiment with original infliximab, in both 
basal and stimulated conditions, we did not observe a significant variation in the 
percentage of PU.1+, IRF4+ Th9 cells in the group of healthy controls, untreated and 
responder RA patients. However, in the group of non responders, the increase in the 
percentage of both PU.1+, IRF4+, IL9+, CD4+ T cells and of central and effector 
memory IL-9+, CD4+ T cells, which was observed following the addiction of infliximab 
originator, did not reach the significance following the addition of the biosimilar 
compound, figg.6,8,9.  Similarly to originator infliximab, the exposure to biosimilar CT-
P13 did not induce a significant modification in naïve, TEMRA and OX40+, IL9+, CD4+ 
T cell percentages in any of the groups of patients; figg.7,10,11. 
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Fig.2. Percentages of IFNγ-, IL-4-, IL-17-, IL-9+, CD4+ T 
lymphocytes in the 4 groups before and after the addition of 
infliximab (Remicade®); *p<0.05, **p<0.01.  
 
                                 Fig.3.  Percentages of PU.1+, IRF4+, IL-9+, CD4+ T lymphocytes 
in the 4 groups before and after the addition of infliximab 




           Fig. 4. Percentage of CD45RA+, CCR7+, IL-9+, CD4+ (naïve) 




   Fig. 5. Percentage of CD45RA-, CCR7+, IL-9+, CD4+ (central 
memory) T cells at baseline and after exposure to infliximab 




   Fig. 6. Percentage of PU.1+, IRF4+, IL-9+, CD4+ T cells at 




   Fig. 7. Percentage of CD45RA+, CCR7+, IL-9+, CD4+ (naïve) T 
cells at baseline and after exposure to branded and biosimilar 
infliximab; *p<0.05, **p<0.01. 
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Fig. 8. Percentage of CD45RA-, CCR7+, IL-9+, CD4+ (central 
memory) T cells at baseline and after exposure to branded and 
biosimilar infliximab; *p<0.05, **p<0.01. 
 
 
Fig. 9. Percentage of CD45RA-, CCR7-, IL-9+, CD4+ (effector 
memory) T cells at baseline and after exposure to branded and 
biosimilar infliximab; *p<0.05, **p<0.01. 
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Fig. 10. Percentage of CD45RA+, CCR7-, IL-9+, CD4+ (terminal 
effector memory) T cells at baseline and after exposure to branded 
and biosimilar infliximab; *p<0.05, **p<0.01. 
 
Fig. 11. Percentage of OX40+, IL-9+, CD4+ T cells at baseline 




   In our work we aimed firstly to evaluate the percentage of Th9 lymphocytes in 
peripheral blood of treated and untreated RA patients, compared to a group of healthy 
controls. Secondly, we performed an immune-stimulation assay in vitro in order to detect 
a possible relationship between Th9 cells and the outcome of a biologic therapy 
(infliximab). Thirdly, we aimed to demonstrate a comparable immunogenic profile 
between branded and biosimilar infliximab, according to the Th9-driven immune 
response.  
   The immunogenicity of a drug depends in fact on the presence of B and T specific 
epitopes contained in the primary aminoacidic sequence or developing during the post-
translational modifications. Since now, the production of ADAs has represented the most 
speculated mechanism of a drug-induced immune response. The production of ADAs 
may be responsible for the development of adverse events or a progressive lack of 
efficacy. Biologic drugs have indeed ameliorated the course and the prognosis of 
rheumatic patients, however a not negligible amount of failure on treatment is reported.   
The immunogenicity of biologic drugs, especially chimeric molecules like infliximab, 
may partly rely on the induction of ADAs. However, we and other authors have 
demonstrated that other immune pathways, like the antigen-specific activation of Th1 or 
Th17 cells may represent an alternative way for rejecting a biological treatment. Th9 cells 
represent a T helper cell subset developing either from naïve or primed Th2 lymphocytes 
in presence of IL-4, TGFβ and OX40 and are characterized by the transcriptional factors 
PU-1 and IRF4 [81]. These cells represent the main source of IL-9, although other cells, 
including Th2 cells, Th17 cells and Treg cells may become specialised in the production 
of this cytokine [82,83]. IL-9 is capable of activating various cells including both Th17 
and Treg lymphocytes [93]. Therefore, according to the local microenvironment, Th9 
lymphocytes may contemporaneously orchestrate the immune response toward 
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autoimmunity/inflammation or tolerance. IL-9 and Th9 cells are increased in 
inflammatory arthritis, connective tissue diseases, autoimmune colitis and autoimmune 
encephalomyelitis [91,92,94,95,96,97]. In line with these data, our results showed an 
increased percentage of Th9 cells, either assessed by cytokine or transcriptional 
phenotype, in the peripheral blood of RA patients when compared to healthy controls.  
These cells were particularly elevated in untreated patients, while the treatment with 
conventional and biologic drugs smoothed their percentage. Following the stimulation 
with original infliximab, cytokine-sorted Th9 cells did not show any variation in any of 
the group examined, however, when sorted according to the transcriptional profile, 
PU.1+, IRF4+ Th9 cells increased in the group of non responder patients. These results 
were confirmed when the experiment was repeated with both central and effector 
memory IL9+ CD4+ T cells, but not with naïve or TEMRA IL9-producer CD4+ T cells. 
The discrepancy in the behaviour of Th9 cells assessed by cytokine or transcriptional 
profile may be explained in light of the pleiotropic pool of IL-9 producer cells (including 
also Treg cells); therefore we chose PU1+, IRF4+ Th9 as most specifically representative 
for the subsequent experiments. PU1+, IRF4+ Th9 cells may increase following an 
antigenic stimulation with infliximab in those patients who discontinued the treatment, 
perhaps following the recall and the activation of central and effector memory Th9 cells. 
When we assessed the response of PU.1+, IRF4+, IL9+ CD4+ lymphocytes to biosimilar 
infliximab we did not find any significant variation in their percentages from baseline in 
any of the 4 groups, although a trend was noticed for central and effector memory cells. 
Therefore, in the group of non responder patients, transcriptional factor-sorted Th9 cells 
increased following the exposure to original but not biosimilar infliximab. This 
discrepancy may be related to several conditions. Firstly, we observed a trend to an 
increased percentage of overall, central memory and effector memory Th9 lymphocytes 
following biosimilar infliximab exposure, although the significance was not reached; this 
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may depend on the scarce number of the enrolled patients (n.20). Furthermore, our 
experiments were carried using one single batch either for Remicade® and Remsima®, 
despite several structural differences may occur from one batch to another of the same 
drug. Finally, the epitopes recognized by Th9 cells on original infliximab may not 
correspond to those belonging to the biosimilar compound, due to some differences in the 
post-translational motifs, like the pattern of glycosylation. Moreover, although the current 
research including RCTs and spontaneous reports has demonstrated a comparable profile 
of immunogenicity between biosimilar and branded infliximab [45,46,55,62,63,64], all 
these studies have addressed the production of ADAs that may depend on different 
immunogenic properties and biologic pathways. Contrary to the group of non responder 
patients, no significant difference between branded and biosimilar infliximab was found 
after stimulating PU.1+, IRF4+, IL9+ CD4+ T lymphocytes from responder patients, and 
this may perhaps account for a more prominent role of Th9 cells in Remicade®- versus 
Remsima®-treated patients, although baseline percentages of these cells did not 
significantly differ between responder and non responder patients. However, both 
responder and non responder patients had received a treatment with Remicade® but not 
with Remsima®, therefore the clinical and biological effects of the biosimilar drug in 
vivo are not available in our cohort.  
 
3.6 Conclusions 
    IL-9 levels are increased in RA patients, in whom this cytokine plays indeed a crucial 
role. Th9 cells are the major producers of IL-9, and their prevalence is higher in RA 
patients than in healthy subjects. According to our results, PU.1+, IRF4+ Th9 cells may 
be involved in orchestrating the immune response against the epitopes of branded 
infliximab; and this condition could rely on the recall and stimulation of both central and 
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effector memory cells. On the other hand, biosimilar infliximab seems not able to activate 
these pools of cells.  
  These data carry a novel point of view in the immunogenicity of anti-TNF agents, 
routinely based on the detection of ADAs. The paradoxical activation of Th9 pool 
following the exposure to infliximab may contribute to the underlying inflammation, thus 
determining a progressive lack of efficacy or the development of adverse effects. However, 
no significant difference was noticed in the PU.1+, IRF4+ Th9 cell percentages in 
Remicade®-responder patients after stimulation test either with biosimilar and branded 
infliximab, proving that in vitro both the two drugs seem to have a comparable efficacy. 
The discrepancy between the Th9-driven immunogenicity of branded and biosimilar 
infliximab in the group of non responder patients, observed in our experiment, may be 
attributed either to methodology, either to the presence of dissimilar epitopes on the two 
compounds or to the involvement of other T cell subsets, like Treg lymphocytes, therefore 
deserving further investigations. 
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